{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:19:26Z","timestamp":1786735166799,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The landscape of advanced melanoma treatments has shifted dramatically in recent years. Target therapy and immunotherapy have changed the management of patients with both metastatic (stage IV according to AJCC 8th ed.) and nodal (stage IIB\/C and III) disease. As the use of novel agents has increased, so have the cutaneous toxicities associated with these medications. While most skin reactions are low-grade and can be managed conservatively with topical therapies, high-grade or life-threatening drug reactions can arise during therapy, requiring prompt dermatologic recognition and treatment. Given the survival benefit attributed to these new agents, treating skin toxicity and maintaining a patient\u2019s quality of life is of paramount importance. Methods: We undertook a prospective, monocentric, and descriptive study in Bologna, Italy, including patients referred to the Oncologic Dermatology Unit of IRCCS AOU of Bologna who developed biopsy-proven cutaneous adverse events (AE) under treatment with immunotherapy for cutaneous melanoma with nodal (stage IIB\/C, III) and metastatic (stage IV) disease from January 2016 to April 2024. Results: In 202 identified patients, 75 (37.5%) developed skin AEs. Ipilimumab was causal for 48.1% of skin AEs, followed by nivolumab (37%) and pembrolizumab (31.4%). Recorded types of skin AEs included erythematous rash, vitiligo, alopecia, lichenoid, maculopapular, acneiform, urticarial, psoriasiform, granulomatous, eczematous, and severe cutaneous AEs, such as Erythema multiforme\/Stevens-Johnson syndrome and bullous autoimmune dermatoses. Most AEs were low-grade [CTCAE 1\u20132] (97%) and typically occurred after 10 weeks of treatment. Conclusions: This study comprehensively describes skin AEs occurring during systemic treatment with ICIs for cutaneous melanoma at a single center.<\/jats:p>","DOI":"10.3390\/cancers16213679","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T08:44:04Z","timestamp":1730364244000},"page":"3679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-4172","authenticated-orcid":false,"given":"Federico","family":"Venturi","sequence":"first","affiliation":[{"name":"Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6595-7776","authenticated-orcid":false,"given":"Giulia","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Scotti","sequence":"additional","affiliation":[{"name":"Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-2861","authenticated-orcid":false,"given":"Emi","family":"Dika","sequence":"additional","affiliation":[{"name":"Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref_1","unstructured":"Ward, W.H., and Farma, J.M. (2017). Epidemiology of Melanoma. Cutaneous Melanoma: Etiology and Therapy, Codon Publications."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","article-title":"Epidemiology of Melanoma","volume":"29","author":"Rigel","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"De Giorgi, V., Magnaterra, E., Zuccaro, B., Magi, S., Magliulo, M., Medri, M., Mazzoni, L., Venturi, F., Silvestri, F., and Tomassini, G.M. (2023). Is Pediatric Melanoma Really That Different from Adult Melanoma? A Multicenter Epidemiological, Clinical and Dermoscopic Study. Cancers, 15.","DOI":"10.3390\/cancers15061835"},{"key":"ref_4","first-page":"326","article-title":"A Single Institute\u2019s Experience on Melanoma Prognosis: A Long-Term Follow-Up","volume":"153","author":"Dika","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous Melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined Anti-PD-1 and Anti-CTLA-4 Checkpoint Blockade: Treatment of Melanoma and Immune Mechanisms of Action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune Checkpoint Inhibitors in Melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A Decade of Checkpoint Blockade Immunotherapy in Melanoma: Understanding the Molecular Basis for Immune Sensitivity and Resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse Cutaneous Toxicities by PD-1\/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Cancer Network JNCCN"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.15215","article-title":"Cutaneous Immune-Related Adverse Events and Photodamaged Skin in Patients with Metastatic Melanoma: Could Nicotinamide Be Useful?","volume":"47","author":"Colombo","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Burzi, L., Alessandrini, A.M., Quaglino, P., Piraccini, B.M., Dika, E., and Ribero, S. (2021). Cutaneous Events Associated with Immunotherapy of Melanoma: A Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143047"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dika, E., Lambertini, M., Gouveia, B., Mussi, M., Marcelli, E., Campione, E., Gurioli, C., Melotti, B., Alessandrini, A., and Ribero, S. (2021). Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061283"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wan, Q., Wei, R., Wei, X., and Deng, Y.-P. (2022). Crosstalk of Four Kinds of Cell Deaths Defines Subtypes of Cutaneous Melanoma for Precise Immunotherapy and Chemotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.998454"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3892\/ijo.2020.5088","article-title":"Cutaneous Melanoma and the Immunotherapy Revolution (Review)","volume":"57","author":"Leonardi","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European Consensus-Based Interdisciplinary Guideline for Melanoma. Part 2: Treatmen\u2014Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9235638","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The Side Effect Registry Immuno-Oncology (SERIO)\u2014A Tool for Systematic Analysis of Immunotherapy-Induced Side Effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jdv.19112","article-title":"Cutaneous Manifestations Induced by Check Point Inhibitors in 120 Melanoma Patients-The European MelSkinTox Study","volume":"37","author":"Cassecuel","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous Immune-Related Adverse Events in Patients with Melanoma Treated with Checkpoint Inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nikolaou, V., Tsimpidakis, A., and Stratigos, A. (2023). Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15072084"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Merli, M., Accorinti, M., Romagnuolo, M., Marzano, A., Di Zenzo, G., Moro, F., Antiga, E., Maglie, R., Cozzani, E., and Parodi, A. (2023). Autoimmune Bullous Dermatoses in Cancer Patients Treated by Immunotherapy: A Literature Review and Italian Multicentric Experience. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1208418"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint Inhibitor-Associated Bullous Cutaneous Immune-Related Adverse Events: A Multicentre Observational Study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/ced.15113","article-title":"BRAF V600K vs. BRAF V600E: A Comparison of Clinical and Dermoscopic Characteristics and Response to Immunotherapies and Targeted Therapies","volume":"47","author":"Zengarini","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jdv.14568","article-title":"Nail Apparatus Melanoma: Dermoscopic and Histopathologic Correlations on a Series of 23 Patients from a Single Centre","volume":"32","author":"Starace","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1684\/ejd.2016.2747","article-title":"Hair and Nail Adverse Events during Treatment with Targeted Therapies for Metastatic Melanoma","volume":"26","author":"Dika","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"ref_28","unstructured":"(2017). Common Terminology Criteria for Adverse Events (CTCAE)."},{"key":"ref_29","first-page":"S0923-7534(24)03910-3","article-title":"Pembrolizumab versus Ipilimumab for Advanced Melanoma: 10-Year Follow-up of the Phase III KEYNOTE-006 Study","volume":"15","author":"Long","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"114327","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-Year Analysis of Adjuvant Pembrolizumab versus Placebo in Stage III Melanoma in the EORTC1325\/KEYNOTE-054 Trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_32","first-page":"e398","article-title":"Short-Term Teledermoscopic Monitoring of Atypical Melanocytic Lesions in the Early Diagnosis of Melanoma: Utility More Apparent than Real","volume":"34","author":"Gori","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","volume":"21","author":"Majem","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"De Giorgi, V., Scarf\u00ec, F., Trane, L., Silvestri, F., Venturi, F., Zuccaro, B., Spinelli, G., Scoccianti, S., De Rosa, F., and Dika, E. (2021). Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting. Cancers, 13.","DOI":"10.3390\/cancers13225706"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1177\/1078155220970621","article-title":"Dermatological Side Effects of Immunotherapy Drugs and Targeted Cancer Therapies: Importance of Dermatology and Oncology Collaboration","volume":"27","author":"Aydemir","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s10147-021-01872-5","article-title":"The Prognostic Impact of Immune-Related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab: A Real-World Multi-Institutional Retrospective Study","volume":"26","author":"Kato","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/ced.14804","article-title":"Lasting Response after Discontinuation of Cemiplimab in a Patient with Locally Advanced Basal Cell Carcinoma","volume":"46","author":"Trane","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Carbone, M.L., Capone, A., Guercio, M., Reddel, S., Silvestris, D.A., Lulli, D., Ramondino, C., Peluso, D., Quintarelli, C., and Volpe, E. (2023). Insight into Immune Profile Associated with Vitiligo Onset and Anti-Tumoral Response in Melanoma Patients Receiving Anti-PD-1 Immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1197630"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/1346-8138.15345","article-title":"Vitiligo Expansion and Extent Correlate with Durable Response in Anti-Programmed Death 1 Antibody Treatment for Advanced Melanoma: A Multi-Institutional Retrospective Study","volume":"47","author":"Matsuya","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2019.12.014","article-title":"Immune-Related Adverse Events Correlate with Clinical Outcomes in NSCLC Patients Treated with Nivolumab: The Italian NSCLC Expanded Access Program","volume":"140","author":"Baldini","year":"2020","journal-title":"Lung Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:24:48Z","timestamp":1760113488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":40,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cancers16213679"],"URL":"https:\/\/doi.org\/10.3390\/cancers16213679","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}